Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Controlled Drug Substances Act (21 USC 13) Stop Oxy Abuse Act (H.R. 1316)
Controlled Drug Substances Act (21 USC 13) Stop Oxy Abuse Act (H.R. 1316)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
OKLAHOMA STATE UNIVERSITY CENTER FOR HEALTH SCIENCES via CAPITOL HILL CONSULTING GROUP
2011 · third_quarter · Q3
General health care issues pertaining to OSU-CHS, including, but not limited to, information technology; access provider education; Veteran's health care; American Recovery and Reinvestment Act (H.R. 1)
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Source: Senate LDA
| PHRMA |
| 13 |
| 2007–2010 |
| MCBRIDE CLINIC | 8 | 2007–2008 |
| NATIONAL KIDNEY FOUNDATION | 7 | 2009 |
| DFB PHARMACEUTICALS INC | 4 | 2008–2009 |
| CSCM, INC. | 3 | 2009 |
| DECHRA VETERINARY PRODUCTS USA | 1 | 2011 |
Life Sciences Jobs and Investment Act of 2011
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; life sciences research tax credit legislation; H.R. 2632/S.1410, the Life Sciences Jobs and Investment Act of 2011
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Medicare coverage of immunosuppressants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S. 565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Health Care Act (H.R.3950)
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Medicare coverage of immunosuppressants; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S. 565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Health Care Act (H.R. 3950)
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Medicare coverage of immunosuppresants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S.565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Care Act (H.R. 3590)
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Medicare coverage of immunosuppresants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S.565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Care Act (H.R. 3590)
Prescription Drug Affordability Act
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
General Healthcare issues, including but not limited to, coverage and reimbursement, drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (H.R. 163); The Pharmaceutical Market Access and Drug Safety Act (S. 525)
Prescription Drug Affordability Act
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (H.R. 163); the Pharmaceutical Market Access and Drug Safety Act (S. 525)
Prescription Drug Affordability Act
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
General Healthcare issues, including but not limited to, coverage and reimbursement, drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (H.R. 163); The Pharmaceutical Market Access and Drug Safety Act (S. 525)
National Oceanic and Atmospheric Administration Act
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Medicare coverage of immunosuppresants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S.565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Care Act (H.R. 3590)
National Oceanic and Atmospheric Administration Act
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Medicare coverage of immunosuppressants; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S. 565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Health Care Act (H.R. 3950)
National Oceanic and Atmospheric Administration Act
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Medicare coverage of immunosuppressants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S. 565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Health Care Act (H.R.3950)
National Oceanic and Atmospheric Administration Act
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Medicare coverage of immunosuppresants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S.565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Care Act (H.R. 3590)
America's Affordable Health Choices Act of 2009
Client: ELI LILLY AND COMPANY · Firm: CAPITOL HILL CONSULTING GROUP
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (H.R. 2184); Follow On Biologics; health reform; America's Affordable Health Choices Act (H.R. 3200); America's Healthy Future Act; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
America's Affordable Health Choices Act of 2009
Client: ELI LILLY AND COMPANY · Firm: CAPITOL HILL CONSULTING GROUP
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (H.R.2184); Follow On Biologics; Health Reform; America's Affordable Health Choices Act (H.R.3200); America's Healthy Future Act; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
America's Affordable Health Choices Act of 2009
Client: NOVARTIS CORPORATION · Firm: CAPITOL HILL CONSULTING GROUP
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug, and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); follow-on biologics; America's Affordable Health Choices Act (H.R. 3200); Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Act (H.R. 3590)
America's Affordable Health Choices Act of 2009
Client: NOVARTIS CORPORATION · Firm: CAPITOL HILL CONSULTING GROUP
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug, and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); follow-on biologics; America's Affordable Health Choices Act (H.R. 3200); Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Act (H.R. 3590)
America's Affordable Health Choices Act of 2009
Client: PHRMA · Firm: CAPITOL HILL CONSULTING GROUP
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Food and Drug Administration Act of 2007 (Public Law no. 110-85); Comparative Effectiveness Research Act (S.3408); American Recovery and Reinvestment Act of 2008 (Public Law No. 111-5); Health Reform; Affordable Healthcare for America Act (HR 3962); Patient Protection And Affordable Care Act (HR 3590); Affordable Health Choices Act (HR 3200); Drug Importation
America's Affordable Health Choices Act of 2009
Client: ELI LILLY AND COMPANY · Firm: CAPITOL HILL CONSULTING GROUP
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (H.R.2184); Follow On Biologics; Health Reform; America's Affordable Health Choices Act (H.R.3200); America's Healthy Future Act; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
America's Affordable Health Choices Act of 2009
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act (H.R. 3200); America's Health Future Act of 2009; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
America's Affordable Health Choices Act of 2009
Client: PURDUE PHARMA LLP · Firm: CAPITOL HILL CONSULTING GROUP
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; America's Affordable Health Choices Act of 2009 (H.R. 3200); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
America's Affordable Health Choices Act of 2009
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; America's Affordable Health Choices Act (H.R. 3200); America's Health Future Act of 2009; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3950)
America's Affordable Health Choices Act of 2009
Client: PURDUE PHARMA LLP · Firm: CAPITOL HILL CONSULTING GROUP
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act of 2009 (H.R. 3200); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
America's Affordable Health Choices Act of 2009
Client: NOVARTIS CORPORATION · Firm: CAPITOL HILL CONSULTING GROUP
General health care issues related to pharmeuceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC9); Public Health Service Act (42 USC 6A); follow-on biologics; America's Affordable Health Choices (H.R. 3200); Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
America's Affordable Health Choices Act of 2009
Client: PHRMA · Firm: CAPITOL HILL CONSULTING GROUP
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Food and Drug Administration Act of 2007 (Public Law no. 110-85); Comparative Effectiveness Research Act (S.3408); American Recovery and Reinvestment Act of 2008 (Public Law No. 111-5); Health Reform; Affordable Healthcare for America Act (HR 3962); Patient Protection And Affordable Care Act (HR 3590); Affordable Health Choices Act (HR 3200); Drug Importation
America's Affordable Health Choices Act of 2009
Client: PURDUE PHARMA LLP · Firm: CAPITOL HILL CONSULTING GROUP
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act of 2009 (H.R. 3200); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
America's Affordable Health Choices Act of 2009
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act (H.R. 3200); America's Health Future Act of 2009; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
To suspend temporarily the duty on BenzÝcd¨indolium, 1-ethyl-2-Ý1,2,3,4-tetrahydro-1- (2-hydroxyethyl)-2,2,4-trimethyl-6-quinolinyl¨-,chloride.
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Medicare coverage of immunosuppressants; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S. 565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Health Care Act (H.R. 3950)
To suspend temporarily the duty on BenzÝcd¨indolium, 1-ethyl-2-Ý1,2,3,4-tetrahydro-1- (2-hydroxyethyl)-2,2,4-trimethyl-6-quinolinyl¨-,chloride.
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Medicare coverage of immunosuppresants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S.565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Care Act (H.R. 3590)
To suspend temporarily the duty on BenzÝcd¨indolium, 1-ethyl-2-Ý1,2,3,4-tetrahydro-1- (2-hydroxyethyl)-2,2,4-trimethyl-6-quinolinyl¨-,chloride.
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Medicare coverage of immunosuppressants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S. 565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Health Care Act (H.R.3950)
To suspend temporarily the duty on BenzÝcd¨indolium, 1-ethyl-2-Ý1,2,3,4-tetrahydro-1- (2-hydroxyethyl)-2,2,4-trimethyl-6-quinolinyl¨-,chloride.
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Medicare coverage of immunosuppresants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S.565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Care Act (H.R. 3590)
Improving Mathematics and Science Teacher Quality Act
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; America's Affordable Health Choices Act (H.R. 3200); America's Health Future Act of 2009; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3950)
Improving Mathematics and Science Teacher Quality Act
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Medicare coverage of immunosuppressants; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S. 565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Health Care Act (H.R. 3950)
Improving Mathematics and Science Teacher Quality Act
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Medicare coverage of immunosuppressants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S. 565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Health Care Act (H.R.3950)
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety; Food and Drug Administration Amendments Act of 2007 (P.L. 110-85); Stop Oxy Abuse Act (H.R. 4956)
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Drug Safety; Food and Drug Administration Amendments Act of 2007 (Public Law No. 110-85); Stop Oxy Abuse Act (H.R.4956)
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; Physician Gifts; Physician Payments Sunshine Act (S.301); Medicare Part D; Non-interference; Medicare Prescription Drugs and Modernization Act (Public Law 108-173)
Physician Payments Sunshine Act of 2009
Client: NOVARTIS CORPORATION · Firm: CAPITOL HILL CONSULTING GROUP
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; Physician Payments Sunshine Act (S.301)
Physician Payments Sunshine Act of 2009
Client: NOVARTIS CORPORATION · Firm: CAPITOL HILL CONSULTING GROUP
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; Physician Payments Sunshine Act (S. 301)
Physician Payments Sunshine Act of 2009
Client: NOVARTIS CORPORATION · Firm: CAPITOL HILL CONSULTING GROUP
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; Physician Payments Sunshine Act (S.301)
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; Physician Gifts; Physician Payments Sunshine Act (S.301); Medicare Part D; Non-interference; Medicare Prescription Drugs and Modernization Act (Public Law 108-173)
Preserve Access to Affordable Generics Act
Client: NOVARTIS CORPORATION · Firm: CAPITOL HILL CONSULTING GROUP
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); follow-on biologics; Preserve Access to Affordable Generics Act (S. 369)
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
General Healthcare issues, including but not limited to, coverage and reimbursement, drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (H.R. 163); The Pharmaceutical Market Access and Drug Safety Act (S. 525)
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
General Healthcare issues, including but not limited to, coverage and reimbursement, drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (H.R. 163); The Pharmaceutical Market Access and Drug Safety Act (S. 525)
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (H.R. 163); the Pharmaceutical Market Access and Drug Safety Act (S. 525)
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Medicare coverage of immunosuppressants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S. 565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Health Care Act (H.R.3950)
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Medicare coverage of immunosuppresants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S.565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Care Act (H.R. 3590)
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Medicare coverage of immunosuppresants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S.565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Care Act (H.R. 3590)
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Medicare coverage of immunosuppressants; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S. 565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Health Care Act (H.R. 3950)
Pharmaceutical Market Access Act of 2009
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
General Healthcare issues, including but not limited to, coverage and reimbursement, drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (H.R. 163); The Pharmaceutical Market Access and Drug Safety Act (S. 525)
Pharmaceutical Market Access Act of 2009
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
General Healthcare issues, including but not limited to, coverage and reimbursement, drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (H.R. 163); The Pharmaceutical Market Access and Drug Safety Act (S. 525)
Pharmaceutical Market Access Act of 2009
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (H.R. 163); the Pharmaceutical Market Access and Drug Safety Act (S. 525)
Enhanced Health Care Value for All Act of 2007
Client: ELI LILLY AND COMPANY · Firm: CAPITOL HILL CONSULTING GROUP
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (H.R.2184); Follow On Biologics; Health Reform; America's Affordable Health Choices Act (H.R.3200); America's Healthy Future Act; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
Enhanced Health Care Value for All Act of 2007
Client: ELI LILLY AND COMPANY · Firm: CAPITOL HILL CONSULTING GROUP
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (H.R. 2184); Follow On Biologics; health reform; America's Affordable Health Choices Act (H.R. 3200); America's Healthy Future Act; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
Enhanced Health Care Value for All Act of 2007
Client: ELI LILLY AND COMPANY · Firm: CAPITOL HILL CONSULTING GROUP
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (H.R.2184); Follow On Biologics; Health Reform; America's Affordable Health Choices Act (H.R.3200); America's Healthy Future Act; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
American Middle Class Tax (AMT) Relief Act of 2007
Client: PHRMA · Firm: CAPITOL HILL CONSULTING GROUP
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Food and Drug Administration Act of 2007 (Public Law no. 110-85); Comparative Effectiveness Research Act (S.3408); American Recovery and Reinvestment Act of 2008 (Public Law No. 111-5); Health Reform; Affordable Healthcare for America Act (HR 3962); Patient Protection And Affordable Care Act (HR 3590); Affordable Health Choices Act (HR 3200); Drug Importation
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: CAPITOL HILL CONSULTING GROUP
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (H.R.2184); Follow On Biologics; Health Reform; America's Affordable Health Choices Act (H.R.3200); America's Healthy Future Act; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
American Middle Class Tax (AMT) Relief Act of 2007
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act (H.R. 3200); America's Health Future Act of 2009; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
American Middle Class Tax (AMT) Relief Act of 2007
Client: PURDUE PHARMA LLP · Firm: CAPITOL HILL CONSULTING GROUP
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act of 2009 (H.R. 3200); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
American Middle Class Tax (AMT) Relief Act of 2007
Client: NOVARTIS CORPORATION · Firm: CAPITOL HILL CONSULTING GROUP
General health care issues related to pharmeuceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC9); Public Health Service Act (42 USC 6A); follow-on biologics; America's Affordable Health Choices (H.R. 3200); Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
American Middle Class Tax (AMT) Relief Act of 2007
Client: NOVARTIS CORPORATION · Firm: CAPITOL HILL CONSULTING GROUP
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug, and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); follow-on biologics; America's Affordable Health Choices Act (H.R. 3200); Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Act (H.R. 3590)
American Middle Class Tax (AMT) Relief Act of 2007
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Medicare coverage of immunosuppresants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S.565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Care Act (H.R. 3590)
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: CAPITOL HILL CONSULTING GROUP
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (H.R. 2184); Follow On Biologics; health reform; America's Affordable Health Choices Act (H.R. 3200); America's Healthy Future Act; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: CAPITOL HILL CONSULTING GROUP
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (H.R.2184); Follow On Biologics; Health Reform; America's Affordable Health Choices Act (H.R.3200); America's Healthy Future Act; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
American Middle Class Tax (AMT) Relief Act of 2007
Client: NOVARTIS CORPORATION · Firm: CAPITOL HILL CONSULTING GROUP
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug, and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); follow-on biologics; America's Affordable Health Choices Act (H.R. 3200); Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Act (H.R. 3590)
American Middle Class Tax (AMT) Relief Act of 2007
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Medicare coverage of immunosuppresants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S.565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Care Act (H.R. 3590)
American Middle Class Tax (AMT) Relief Act of 2007
Client: PURDUE PHARMA LLP · Firm: CAPITOL HILL CONSULTING GROUP
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act of 2009 (H.R. 3200); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
American Middle Class Tax (AMT) Relief Act of 2007
Client: PURDUE PHARMA LLP · Firm: CAPITOL HILL CONSULTING GROUP
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; America's Affordable Health Choices Act of 2009 (H.R. 3200); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
American Middle Class Tax (AMT) Relief Act of 2007
Client: PHRMA · Firm: CAPITOL HILL CONSULTING GROUP
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Food and Drug Administration Act of 2007 (Public Law no. 110-85); Comparative Effectiveness Research Act (S.3408); American Recovery and Reinvestment Act of 2008 (Public Law No. 111-5); Health Reform; Affordable Healthcare for America Act (HR 3962); Patient Protection And Affordable Care Act (HR 3590); Affordable Health Choices Act (HR 3200); Drug Importation
American Middle Class Tax (AMT) Relief Act of 2007
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act (H.R. 3200); America's Health Future Act of 2009; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act of 2009 (H.R. 3200); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
Superfund Polluter Pays Act
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act (H.R. 3200); America's Health Future Act of 2009; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
Superfund Polluter Pays Act
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act (H.R. 3200); America's Health Future Act of 2009; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
Superfund Polluter Pays Act
Client: NOVARTIS CORPORATION · Firm: CAPITOL HILL CONSULTING GROUP
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug, and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); follow-on biologics; America's Affordable Health Choices Act (H.R. 3200); Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Act (H.R. 3590)
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Food and Drug Administration Act of 2007 (Public Law no. 110-85); Comparative Effectiveness Research Act (S.3408); American Recovery and Reinvestment Act of 2008 (Public Law No. 111-5); Health Reform; Affordable Healthcare for America Act (HR 3962); Patient Protection And Affordable Care Act (HR 3590); Affordable Health Choices Act (HR 3200); Drug Importation
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act of 2009 (H.R. 3200); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
Superfund Polluter Pays Act
Client: NOVARTIS CORPORATION · Firm: CAPITOL HILL CONSULTING GROUP
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug, and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); follow-on biologics; America's Affordable Health Choices Act (H.R. 3200); Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Act (H.R. 3590)
Superfund Polluter Pays Act
Client: ELI LILLY AND COMPANY · Firm: CAPITOL HILL CONSULTING GROUP
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (H.R.2184); Follow On Biologics; Health Reform; America's Affordable Health Choices Act (H.R.3200); America's Healthy Future Act; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Food and Drug Administration Act of 2007 (Public Law no. 110-85); Comparative Effectiveness Research Act (S.3408); American Recovery and Reinvestment Act of 2008 (Public Law No. 111-5); Health Reform; Affordable Healthcare for America Act (HR 3962); Patient Protection And Affordable Care Act (HR 3590); Affordable Health Choices Act (HR 3200); Drug Importation
Superfund Polluter Pays Act
Client: ELI LILLY AND COMPANY · Firm: CAPITOL HILL CONSULTING GROUP
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (H.R.2184); Follow On Biologics; Health Reform; America's Affordable Health Choices Act (H.R.3200); America's Healthy Future Act; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
Superfund Polluter Pays Act
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; America's Affordable Health Choices Act (H.R. 3200); America's Health Future Act of 2009; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3950)
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; America's Affordable Health Choices Act of 2009 (H.R. 3200); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
Superfund Polluter Pays Act
Client: NOVARTIS CORPORATION · Firm: CAPITOL HILL CONSULTING GROUP
General health care issues related to pharmeuceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC9); Public Health Service Act (42 USC 6A); follow-on biologics; America's Affordable Health Choices (H.R. 3200); Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
Superfund Polluter Pays Act
Client: ELI LILLY AND COMPANY · Firm: CAPITOL HILL CONSULTING GROUP
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (H.R. 2184); Follow On Biologics; health reform; America's Affordable Health Choices Act (H.R. 3200); America's Healthy Future Act; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
Comparative Effectiveness Research Act of 2008
Client: PHRMA · Firm: CAPITOL HILL CONSULTING GROUP
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Food and Drug Administration Act of 2007 (Public Law no. 110-85); Comparative Effectiveness Research Act (S.3408); American Recovery and Reinvestment Act of 2008 (Public Law No. 111-5); Health Reform; Affordable Healthcare for America Act (HR 3962); Patient Protection And Affordable Care Act (HR 3590); Affordable Health Choices Act (HR 3200); Drug Importation
Comparative Effectiveness Research Act of 2008
Client: PHRMA · Firm: CAPITOL HILL CONSULTING GROUP
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Food and Drug Administration Act of 2007 (Public Law no. 110-85); Comparative Effectiveness Research Act (S.3408); American Recovery and Reinvestment Act of 2008 (Public Law No. 111-5); Health Reform; Affordable Healthcare for America Act (HR 3962); Patient Protection And Affordable Care Act (HR 3590); Affordable Health Choices Act (HR 3200); Drug Importation
Comparative Effectiveness Research Act of 2008
Client: ELI LILLY AND COMPANY · Firm: CAPITOL HILL CONSULTING GROUP
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (H.R.2184); Follow On Biologics; Health Reform; America's Affordable Health Choices Act (H.R.3200); America's Healthy Future Act; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
Comparative Effectiveness Research Act of 2008
Client: ELI LILLY AND COMPANY · Firm: CAPITOL HILL CONSULTING GROUP
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (H.R. 2184); Follow On Biologics; health reform; America's Affordable Health Choices Act (H.R. 3200); America's Healthy Future Act; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
Comparative Effectiveness Research Act of 2008
Client: ELI LILLY AND COMPANY · Firm: CAPITOL HILL CONSULTING GROUP
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (H.R.2184); Follow On Biologics; Health Reform; America's Affordable Health Choices Act (H.R.3200); America's Healthy Future Act; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: CAPITOL HILL CONSULTING GROUP
general healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Follow-on Biologics; Comparative Effectiveness; Comparative Effectiveness Research Act (S.3408); Enhanced Health Care Value for All Act (HR2184); Promoting Innovation and Access to Life-saving Medicine Act (HR1427/S.726); Biologics Price Competition and Innovation Act of 2007 (S.1695); Pathway for Biosimilars Acr (HR1548); Health Reform; America's Affordable Health Choices Act (HR3200); America's Healthy Future Act
Promoting Innovation and Access to Life-Saving Medicine Act
Client: NOVARTIS CORPORATION · Firm: CAPITOL HILL CONSULTING GROUP
general healthcare issues related to pharmaceutical and biological products; Federal Food, Drug, and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Promoting Innovation and Access to Lifesaving Medicine Act (HR1427/S.726); Pathway for Biosimilars Act (HR1548); Biologics Price Competition and Innovation Act of 2007; drug safety; follow-on biologics; America's Affordable Health Choices Act (HR3200); America's Healthy Future Act
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: CAPITOL HILL CONSULTING GROUP
general healthcare issues related to pharmaceutical and biological products; Federal, Food Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Follow-on Biologics; Comparative Effectiveness: Comparative Effectiveness Reserach Act (S.3408); Enhanced Health Care Value for All Act (HR2184); Promoting Innovation and Access to Life-saving Medicine Act (HR1427/S.726); Biologics Price Competition and Innovation Act of 2007 (S.1695); Pathway for Biosimilars Act (HR1548); Health Reform; Affordable Health Choices Act
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: CAPITOL HILL CONSULTING GROUP
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); FDA Globalization Act (H.R. 759); Follow-on Biologics; Comparative Effectiveness: Comparative Effectiveness Research Ace (S. 3408); Enhanced Health Care Value for All Act (H.R. 2184); Promoting Innovation and Access to Life-saving Medicine Act (H.R. 1427/S.726); Biologics Price Competition and Innovation Act (S.1695)
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Medicare coverage of immunosuppressants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S. 565); America's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R.3862); Patient Protection and Affordable Care Act (H.R. 3590)
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
issues related to Medicare coverage of immunosuppressants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR1458/S.565); America's Affordable Health Choices Act (HR3200); America's Healthy Future Act of 2009
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
issues related to: Medicare coverage of immunosuppressants; Medicare Part D's six classes of clinical concern, Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act HR1458/S.565
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: NATIONAL KIDNEY FOUNDATION · Firm: CAPITOL HILL CONSULTING GROUP
Medicare Coverage of Immunosuppressants; Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patient Act (HR1458/S.565); America's Affordable Healthy Choices Act (HR3200); America's Healthy Future Act of 2009
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
issues related to: Medicare coverage of immunosuppressants; Medicare Part D's six classes of clinical concern, Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act HR1458/S.565
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US · Firm: CAPITOL HILL CONSULTING GROUP
issues related to Medicare coverage of immunosuppressants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR1458/S.565); America's Affordable Health Choices Act (HR3200); America's Healthy Future Act of 2009
General appropriations for OSU-CHS; Labor, HHS, Education Appropriations bills; CJS Appropriations bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
ENDO PHARMACEUTICALS via CAPITOL HILL CONSULTING GROUP
2011 · third_quarter · 3A
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; life sciences research tax credit legislation; H.R. 2632/S.1410, the Life Sciences Jobs and Investment Act of 2011
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDO PHARMACEUTICALS via CAPITOL HILL CONSULTING GROUP
2011 · third_quarter · Q3
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS CORPORATION via CAPITOL HILL CONSULTING GROUP
2011 · third_quarter · Q3
General patent issues; America Invents Act (S. 23)
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
General FDA funding issues; FY2012 Labor-HHS-Education Appropriations; Pandemic vaccine issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Biosimilars; Patient Protection and Affordable Care Act (P.L. 111-148)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PURDUE PHARMA LLP via CAPITOL HILL CONSULTING GROUP
2011 · third_quarter · Q3
Controlled Drug Substances Act (21 USC 13) Stop Oxy Abuse Act (H.R. 1316)
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US via CAPITOL HILL CONSULTING GROUP
2011 · third_quarter · 3T
Issues pertaining to antimicrobial resistance; community and health care associated infections and organ transplanation; Patient Protection and Affordable Care Act (P.L. 111-148); Prescription Drug User Fee Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OKLAHOMA STATE UNIVERSITY CENTER FOR HEALTH SCIENCES via CAPITOL HILL CONSULTING GROUP
2011 · second_quarter · Q2
General appropriations for OSU-CHS; Labor, HHS, Education Appropriations bills; CJS Appropriations bill
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
General health care issues pertaining to OSU-CHS, including, but not limited to, information technology; access provider education; Veteran's health care; American Recovery and Reinvestment Act (H.R. 1)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
ENDO PHARMACEUTICALS via CAPITOL HILL CONSULTING GROUP
2011 · second_quarter · Q2
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PURDUE PHARMA LLP via CAPITOL HILL CONSULTING GROUP
2011 · second_quarter · Q2
Controlled Drug Substances Act (21 USC 13) Stop Oxy Abuse Act (H.R. 1316)
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS CORPORATION via CAPITOL HILL CONSULTING GROUP
2011 · second_quarter · Q2
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Biosimilars; Patient Protection and Affordable Care Act (P.L. 111-148)
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
General patent issues; America Invents Act (S. 23)
ASTELLAS PHARMA US via CAPITOL HILL CONSULTING GROUP
2011 · second_quarter · Q2
Issues pertaining to antimicrobial resistance; community and health care associated infections and organ transplanatation; Patient Protection and Affordable Care Act (P.L. 111-148); Prescription Drug User Fee Act
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement of pharmaceuticals
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DECHRA VETERINARY PRODUCTS USA via CAPITOL HILL CONSULTING GROUP
2011 · second_quarter · RR
Federal Food, Drug, and Cosmetic Act, including issues relating to the extra-label use of animal drug products.
Federal Food, Drug, and Cosmetic Act, including issues relating to the extra-label use of animal drug products.
Federal Food, Drug, and Cosmetic Act, including issues relating to the extra-label use of animal drug products.
OKLAHOMA STATE UNIVERSITY CENTER FOR HEALTH SCIENCES via CAPITOL HILL CONSULTING GROUP
2011 · first_quarter · Q1
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
General health care issues pertaining to OSU-CHS, including, but not limited to, information technology; access provider education; Veteran's health care; American Recovery and Reinvestment Act (H.R. 1)
General appropriations for OSU-CHS; Labor, HHS, Education Appropriations bills; CJS Appropriations bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
ENDO PHARMACEUTICALS via CAPITOL HILL CONSULTING GROUP
2011 · first_quarter · Q1
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PURDUE PHARMA LLP via CAPITOL HILL CONSULTING GROUP
2011 · first_quarter · Q1
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Controlled Drug Substances Act (21 USC 13)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS CORPORATION via CAPITOL HILL CONSULTING GROUP
2011 · first_quarter · Q1
General patent issues; America Invents Act (S. 23)
General FDA funding issues; FY2012 Labor-HHS-Education Appropriations; Pandemic vaccine issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Biosimilars; Patient Protection and Affordable Care Act (P.L. 111-148)
ASTELLAS PHARMA US via CAPITOL HILL CONSULTING GROUP
2011 · first_quarter · Q1
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement of pharmaceuticals
Issues pertaining to antimicrobial resistance; community and health care associated infections and organ transplantation; Patient Protection and Affordable Care Act (P.L. 111-148); Prescription Drug User Fee Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PURDUE PHARMA LLP via CAPITOL HILL CONSULTING GROUP
2010 · fourth_quarter · Q4
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety
Controlled Drug Substances Act (21 USC 13)
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS CORPORATION via CAPITOL HILL CONSULTING GROUP
2010 · fourth_quarter · Q4
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); follow-on biologics; Preserve Access to Affordable Generics Act (S. 369)
General patent issues
General FDA funding issues; FY2011 Labor-HHS-Education Appropriations; FY2011 Supplemental Appropriations; Pandemic vaccine issues
ELI LILLY AND COMPANY via CAPITOL HILL CONSULTING GROUP
2010 · fourth_quarter · 4T
General health care issues related to the pharmaceutical and biological products; Federal Food, Drug, and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A)
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDO PHARMACEUTICALS via CAPITOL HILL CONSULTING GROUP
2010 · fourth_quarter · Q4
General health care issues, including, but not limited to, coverage and reimbursement; drug importation
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US via CAPITOL HILL CONSULTING GROUP
2010 · fourth_quarter · Q4
Issues pertaining to antimicrobial resistance; community and health care associated infections and organ transplantation; STARR Act
Issues related to Medicare coverage of immunosuppressants
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OKLAHOMA STATE UNIVERSITY CENTER FOR HEALTH SCIENCES via CAPITOL HILL CONSULTING GROUP
2010 · fourth_quarter · Q4
General health care issues pertaining to OSU-CHS, including, but not limited to, information technology; access provider education; Veteran's health care; American Recovery and Reinvestment Act (H.R. 1)
General appropriations for OSU-CHS; FY2011 Labor, HHS, Education Appropriations bills; CJS Appropriations bill
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
ASTELLAS PHARMA US via CAPITOL HILL CONSULTING GROUP
2010 · third_quarter · 3A
Issues related to Medicare coverage of immunosuppressants; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S. 565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Health Care Act (H.R. 3950)
Issues pertaining to antimicrobial resistance; community and health care associated infections and organ transplantation; STARR Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS CORPORATION via CAPITOL HILL CONSULTING GROUP
2010 · third_quarter · 3A
General health care issues related to pharmeuceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC9); Public Health Service Act (42 USC 6A); follow-on biologics; America's Affordable Health Choices (H.R. 3200); Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
General patent issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; Physician Payments Sunshine Act (S. 301)
OKLAHOMA STATE UNIVERSITY CENTER FOR HEALTH SCIENCES via CAPITOL HILL CONSULTING GROUP
2010 · third_quarter · Q3
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
General health care issues pertaining to OSU-CHS, including, but not limited to, information technology; access provider education; Veteran's health care; American Recovery and Reinvestment Act (H.R. 1)
General appropriations for OSU-CHS; FY2011 Labor/HHS/Education Appropriations bills; CJS Appropriations bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
ELI LILLY AND COMPANY via CAPITOL HILL CONSULTING GROUP
2010 · third_quarter · Q3
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (H.R. 2184); Follow On Biologics; health reform; America's Affordable Health Choices Act (H.R. 3200); America's Healthy Future Act; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDO PHARMACEUTICALS via CAPITOL HILL CONSULTING GROUP
2010 · third_quarter · Q3
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (H.R. 163); the Pharmaceutical Market Access and Drug Safety Act (S. 525)
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; America's Affordable Health Choices Act (H.R. 3200); America's Health Future Act of 2009; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3950)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PURDUE PHARMA LLP via CAPITOL HILL CONSULTING GROUP
2010 · third_quarter · Q3
Controlled Drug Substances Act (21 USC 13)
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; America's Affordable Health Choices Act of 2009 (H.R. 3200); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety; Food and Drug Administration Amendments Act of 2007 (P.L. 110-85); Stop Oxy Abuse Act (H.R. 4956)
ASTELLAS PHARMA US via CAPITOL HILL CONSULTING GROUP
2010 · third_quarter · Q3
Issues related to Medicare coverage of immunosuppressants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S. 565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Health Care Act (H.R.3950)
Issues pertaining to antimicrobial resistance; community and health care associated infections and organ transplantation; STARR Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PURDUE PHARMA LLP via CAPITOL HILL CONSULTING GROUP
2010 · second_quarter · Q2
Controlled Drug Substances Act (21 USC 13)
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Drug Safety; Food and Drug Administration Amendments Act of 2007 (Public Law No. 110-85); Stop Oxy Abuse Act (H.R.4956)
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act of 2009 (H.R. 3200); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
PHRMA via CAPITOL HILL CONSULTING GROUP
2010 · second_quarter · Q2
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Food and Drug Administration Act of 2007 (Public Law no. 110-85); Comparative Effectiveness Research Act (S.3408); American Recovery and Reinvestment Act of 2008 (Public Law No. 111-5); Health Reform; Affordable Healthcare for America Act (HR 3962); Patient Protection And Affordable Care Act (HR 3590); Affordable Health Choices Act (HR 3200); Drug Importation
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; Physician Gifts; Physician Payments Sunshine Act (S.301); Medicare Part D; Non-interference; Medicare Prescription Drugs and Modernization Act (Public Law 108-173)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS CORPORATION via CAPITOL HILL CONSULTING GROUP
2010 · second_quarter · Q2
General Patent Issues
FDA funding issues, generally, FY2010 Labor-HHS Appropriations; FY2010 Supplemental Appropriations; Pandemic vaccine issues;
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug, and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); follow-on biologics; America's Affordable Health Choices Act (H.R. 3200); Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Act (H.R. 3590)
ENDO PHARMACEUTICALS via CAPITOL HILL CONSULTING GROUP
2010 · second_quarter · Q2
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act (H.R. 3200); America's Health Future Act of 2009; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
General Healthcare issues, including but not limited to, coverage and reimbursement, drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (H.R. 163); The Pharmaceutical Market Access and Drug Safety Act (S. 525)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via CAPITOL HILL CONSULTING GROUP
2010 · second_quarter · Q2
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (H.R.2184); Follow On Biologics; Health Reform; America's Affordable Health Choices Act (H.R.3200); America's Healthy Future Act; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OKLAHOMA STATE UNIVERSITY CENTER FOR HEALTH SCIENCES via CAPITOL HILL CONSULTING GROUP
2010 · second_quarter · Q2
general approprations for OSU-CHS; FY2011 Labor/HHS/Education Approprations Bills; CJS Appropriations Bill
general healthcare issues pertaining to OSU-CHS, including but not limited to: information technology; access provider education; Veteran's Healthcare; American Recovery and Reinvestment Act (H.R. 1)
general Medicare and Medicaid issues, including but not limited to, coverage and reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
ASTELLAS PHARMA US via CAPITOL HILL CONSULTING GROUP
2010 · second_quarter · Q2
Issues related to Medicare coverage of immunosuppresants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S.565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Care Act (H.R. 3590)
Issues pertaining to antimicrobial resistance; community and healthcare associated infections and organ transplantation; STARR Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS CORPORATION via CAPITOL HILL CONSULTING GROUP
2010 · first_quarter · Q1
General Patent Issues
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; Physician Payments Sunshine Act (S.301)
FDA funding issues, generally, FY2010 Labor-HHS Appropriations; FY2010 Supplemental Appropriations;; Pandemic vaccine issues; American Recovery and Reinvestment Act (H.R. 1)
PURDUE PHARMA LLP via CAPITOL HILL CONSULTING GROUP
2010 · first_quarter · Q1
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act of 2009 (H.R. 3200); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Drug Safety; Food and Drug Administration Amendments Act of 2007 (Public Law No. 110-85)
Controlled Drug Substances Act (21 USC 13)
OKLAHOMA STATE UNIVERSITY CENTER FOR HEALTH SCIENCES via CAPITOL HILL CONSULTING GROUP
2010 · first_quarter · Q1
General appropriations for OSU-CHS; FY2011 Labor/HHS/Education Appropriations Bills
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement
General healthcare issues pertaining to OSU-CHS, including but not limited to:information technology; access provider education; Veteran's healthcare; American Recovery and Reinvestment Act (HR 1)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
PHRMA via CAPITOL HILL CONSULTING GROUP
2010 · first_quarter · Q1
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; Physician Gifts; Physician Payments Sunshine Act (S.301); Medicare Part D; Non-interference; Medicare Prescription Drugs and Modernization Act (Public Law 108-173)
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Food and Drug Administration Act of 2007 (Public Law no. 110-85); Comparative Effectiveness Research Act (S.3408); American Recovery and Reinvestment Act of 2008 (Public Law No. 111-5); Health Reform; Affordable Healthcare for America Act (HR 3962); Patient Protection And Affordable Care Act (HR 3590); Affordable Health Choices Act (HR 3200); Drug Importation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via CAPITOL HILL CONSULTING GROUP
2010 · first_quarter · Q1
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (H.R.2184); Follow On Biologics; Health Reform; America's Affordable Health Choices Act (H.R.3200); America's Healthy Future Act; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDO PHARMACEUTICALS via CAPITOL HILL CONSULTING GROUP
2010 · first_quarter · Q1
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act (H.R. 3200); America's Health Future Act of 2009; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
General Healthcare issues, including but not limited to, coverage and reimbursement, drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (H.R. 163); The Pharmaceutical Market Access and Drug Safety Act (S. 525)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US via CAPITOL HILL CONSULTING GROUP
2010 · first_quarter · Q1
Issues pertaining to antimicrobial resistance; community and healthcare associated infections and organ transplantation; STARR Act; Drug Importation; Follow-on Biologics
Issues related to Medicare coverage of immunosuppresants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S.565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Care Act (H.R. 3590)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL KIDNEY FOUNDATION via CAPITOL HILL CONSULTING GROUP
2009 · fourth_quarter · 4T
Medicare Coverage of Immunosuppressants; Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patient Act (HR 1458/S.565); America's Affordable Healthy Choices Act (HR 3200); America's Healthy Future Act of 2009
Assist the NKF in securing federal funding for programs aimed at screening and preventing chronic kidney disease; Requesting funding for the Kidney Early Evaluation Program (KEEP)
Assist the NKF in securing federal funding for programs aimed at screening and preventing chronic kidney disease; Requesting funding for the Kidney Early Evaluation Program (KEEP); S.565 Immunosupprossive Drug Benefit under Medicare and America's Healthy Future Act
NOVARTIS CORPORATION via CAPITOL HILL CONSULTING GROUP
2009 · fourth_quarter · Q4
FDA funding issues, generally, FY2010 Labor-HHS Appropriations; FY2010 Supplemental Appropriations;; Pandemic vaccine issues; American Recovery and Reinvestment Act (H.R. 1)
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; Physician Payments Sunshine Act (S.301)
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug, and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); follow-on biologics; America's Affordable Health Choices Act (H.R. 3200); Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Act (H.R. 3590)
PURDUE PHARMA LLP via CAPITOL HILL CONSULTING GROUP
2009 · fourth_quarter · Q4
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act of 2009 (H.R. 3200); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
Controlled Drug Substances Act (21 USC 13)
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Drug Safety; Food and Drug Administration Amendments Act of 2007 (Public Law No. 110-85)
ELI LILLY AND COMPANY via CAPITOL HILL CONSULTING GROUP
2009 · fourth_quarter · Q4
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (H.R.2184); Follow On Biologics; Health Reform; America's Affordable Health Choices Act (H.R.3200); America's Healthy Future Act; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CSCM, INC. via CAPITOL HILL CONSULTING GROUP
2009 · fourth_quarter · 4T
Reimbursement of outpatient medical imaging services provided under Medicare Part B. Healthcare reform legislation, generally; American's Affordable Health Choices Act (H.R. 3200)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US via CAPITOL HILL CONSULTING GROUP
2009 · fourth_quarter · Q4
Issues pertaining to antimicrobial resistance; community and healthcare associated infections and organ transplantation; STARR Act; Drug Importation; Follow-on Biologics
Issues related to Medicare coverage of immunosuppressants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S. 565); America's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R.3862); Patient Protection and Affordable Care Act (H.R. 3590)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDO PHARMACEUTICALS via CAPITOL HILL CONSULTING GROUP
2009 · fourth_quarter · Q4
General Healthcare issues, including but not limited to, coverage and reimbursement, drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (H.R. 163); The Pharmaceutical Market Access and Drug Safety Act (S. 525)
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act (H.R. 3200); America's Health Future Act of 2009; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via CAPITOL HILL CONSULTING GROUP
2009 · fourth_quarter · Q4
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Food and Drug Administration Act of 2007 (Public Law no. 110-85); Comparative Effectiveness Research Act (S.3408); American Recovery and Reinvestment Act of 2008 (Public Law No. 111-5); Health Reform; Affordable Healthcare for America Act (HR 3962); Patient Protection And Affordable Care Act (HR 3590); Affordable Health Choices Act (HR 3200); Drug Importation
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; Physician Gifts; Physician Payments Sunshine Act (S.301); Medicare Part D; Non-interference; Medicare Prescription Drugs and Modernization Act (Public Law 108-173)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OKLAHOMA STATE UNIVERSITY CENTER FOR HEALTH SCIENCES via CAPITOL HILL CONSULTING GROUP
2009 · fourth_quarter · Q4
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement
General healthcare issues pertaining to OSU-CHS, including but not limited to: information technology; access provider education; Veteran's healthcare; American Recovery and Reinvestment Act (HR1)
General appropriations for OSU-CHS; FY2010 Labor/HHS/Education Appropriations Bills
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
ASTELLAS PHARMA US via CAPITOL HILL CONSULTING GROUP
2009 · third_quarter · 3A
issues pertaining to antimicrobial resistance; community and healthcare associated infections and organ transplantation; STAAR Act
issues related to Medicare coverage of immunosuppressants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR1458/S.565); America's Affordable Health Choices Act (HR3200); America's Healthy Future Act of 2009
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US via CAPITOL HILL CONSULTING GROUP
2009 · second_quarter · 2A
issues related to: Medicare coverage of immunosuppressants; Medicare Part D's six classes of clinical concern, Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act HR1458/S.565
issues pertaining to antimicrobial resistance; community and healthcare associated infections and organ transplantation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US via CAPITOL HILL CONSULTING GROUP
2009 · first_quarter · 1A
Issues pertaining to antimicrobial resistance; Issues pertaining to community and healthcare associated infections; Issues pertaining to organ transplantation.
Issues related to: Medicare coverage of immunosuppressants, Medicare Part D's six classes of clinical concern, Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Ace of 2007
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL KIDNEY FOUNDATION via CAPITOL HILL CONSULTING GROUP
2009 · third_quarter · 3A
Assist the NKF in securing federal funding for programs aimed at screening and preventing chronic kidney disease; Requesting funding for the Kidney Early Evaluation Program (KEEP)
Medicare Coverage of Immunosuppressants; Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patient Act (HR1458/S.565); America's Affordable Healthy Choices Act (HR3200); America's Healthy Future Act of 2009
Assist the NKF in securing federal funding for programs aimed at screening and preventing chronic kidney disease; Requesting funding for the Kidney Early Evaluation Program (KEEP); S.565 Immunosupprossive Drug Benefit under Medicare and America's Healthy Future Act
NATIONAL KIDNEY FOUNDATION via CAPITOL HILL CONSULTING GROUP
2009 · third_quarter · Q3
Medicare Coverage of Immunosuppressants; Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patient Act (HR1458/S.565); America's Affordable Healthy Choices Act (HR3200); America's Healthy Future Act of 2009
Assist the NKF in securing federal funding for programs aimed at screening and preventing chronic kidney disease; Requesting funding for the Kidney Early Evaluation Program (KEEP)
Assist the NKF in securing federal funding for programs aimed at screening and preventing chronic kidney disease; Requesting funding for the Kidney Early Evaluation Program (KEEP)
ELI LILLY AND COMPANY via CAPITOL HILL CONSULTING GROUP
2009 · third_quarter · Q3
general healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Follow-on Biologics; Comparative Effectiveness; Comparative Effectiveness Research Act (S.3408); Enhanced Health Care Value for All Act (HR2184); Promoting Innovation and Access to Life-saving Medicine Act (HR1427/S.726); Biologics Price Competition and Innovation Act of 2007 (S.1695); Pathway for Biosimilars Acr (HR1548); Health Reform; America's Affordable Health Choices Act (HR3200); America's Healthy Future Act
general Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act (HR3200); America's Healthy Future Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US via CAPITOL HILL CONSULTING GROUP
2009 · third_quarter · Q3
issues related to Medicare coverage of immunosuppressants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR1458/S.565); America's Affordable Health Choices Act (HR3200); America's Healthy Future Act of 2009
issues pertaining to antimicrobial resistance; community and healthcare associated infections and organ transplantation; STAAR Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via CAPITOL HILL CONSULTING GROUP
2009 · third_quarter · Q3
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; Physician Gifts; Physician Payments Sunshine Act (S.301); Medicare Part D; Non-interference; Medicare Prescription Drugs and Modernization Act (Public Law 108-173); America's Affordable Health Choices Act (HR3200); America's Healthy Future Ace
general healthcare issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Drug Safety; Food and Drug Administration Amendments Act of 2007 (Public Law No. 110-85); Comparative Effectiveness; Comparative Effectiveness Research Act (S.3408); American Recovery and Reinvestment Act of 2008 (Public Law No. 111-5); Healthcare Reform; Affordable Health Choices Act; Drug Imporation, including The Pharmaceutical Market Access Act (S.80) and The Pharmaceutical Market Access and Drug Safety Act (S.525)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PURDUE PHARMA LLP via CAPITOL HILL CONSULTING GROUP
2009 · third_quarter · Q3
general Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act of 2009 (HR3200); America's Healthy Future Act of 2009
general healthcare issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety; Food and Drug Administration Amendments Act of 2007 (Public Law No. 110-85)
Controlled Drug Substances Act (21 USC 13)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDO PHARMACEUTICALS via CAPITOL HILL CONSULTING GROUP
2009 · third_quarter · Q3
general Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act (HR3200); America's Health Future Act of 2009
general Medicare and Medicaid issues, including but not limited to, coverage and reimbursement. General healthcare issues, including but not limited to, drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (HR163); The Pharmaceutical Market Access and Drug Safety Act (S.525)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS CORPORATION via CAPITOL HILL CONSULTING GROUP
2009 · third_quarter · Q3
general patent issues
general healthcare issues related to pharmaceutical and biological products; Federal Food, Drug, and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Promoting Innovation and Access to Lifesaving Medicine Act (HR1427/S.726); Pathway for Biosimilars Act (HR1548); Biologics Price Competition and Innovation Act of 2007; drug safety; follow-on biologics; America's Affordable Health Choices Act (HR3200); America's Healthy Future Act
FDA funding issues, generally, FY2010 Labor-HHS Appropriations; FY2010 Supplemental Appropriations; Pandemic vaccine issues; American Recovery and Reinvestment Act (HR1)
OKLAHOMA STATE UNIVERSITY CENTER FOR HEALTH SCIENCES via CAPITOL HILL CONSULTING GROUP
2009 · third_quarter · Q3
general healthcare issues pertaining to OSU-CHS, including but not limited to: information technology; access provider education; Vetaran's healthcare; American Recovery and Reinvestment Act (HR1)
general appropriations for OSU-CHS; FY2010 Labor/HHS/Education Appropriations Bills
general Medicare and Medicaid issues, including but not limited to, coverage and reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
CSCM, INC. via CAPITOL HILL CONSULTING GROUP
2009 · third_quarter · Q3
Reimbursement of outpatient medical imaging services provided under Medicare Part B. Healthcare reform legislation, generally; American's Affordable Health Choices Act (HR3200); America's Health Forms Act of 2009
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CSCM, INC. via CAPITOL HILL CONSULTING GROUP
2009 · third_quarter · RR
Reimbursement of outpatient medical imaging services provided under Medicare Part B. Health care reform legislation, generally
NOVARTIS CORPORATION via CAPITOL HILL CONSULTING GROUP
2009 · second_quarter · Q2
general patent issues
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; Physician gifts; Physician Payments Sunshine Act (S.301)
general healthcare issues related to pharmaceutical and biological products; Federal Food, Drug, and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); FDA Globalization Act (HR759); Promoting Innovation and Access to Lifesaving Medicine Act (HE1427/S.726); Pathway for Biosimilars Act (HR1548); Biologics Price Competition and Innovation Ace of 2007; drug safety; follow-on biologics
PHRMA via CAPITOL HILL CONSULTING GROUP
2009 · second_quarter · Q2
general healthcare issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Drug Safety: Food and Drug Administration Amendments Act of 2007 (Public Law No. 110-85); FDA Globalization Act (HR 759); Comparative Effectiveness: Comparative Effectiveness Research Act (S.3408); American Recovery and Reinvestment Act of 2008 (Public Law No. 111-5); health care reform; Affordable Health Choices Act, Drug Importation, including The Pharmaceutical Market Access Act (S.80) and The Pharmaceutical Market Access and Drug Safety Act (S.525)
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; Physician Gifts: Physician Payments Sunshine Act (S.301): Medicare Part D: Non-interference; Medicare Prescription Drugs and Modernization Act (Public Law 108-173)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL KIDNEY FOUNDATION via CAPITOL HILL CONSULTING GROUP
2009 · second_quarter · Q2
Assist the NKF in securing federal funding for programs aimed at screening and preventing chronic kidney disease; Requesting funding for the Kidney Early Evaluation Program (KEEP).
Assist the NKF in securing federal funding for programs aimed at screening and preventing chronic kidney disease; Requesting funding for the Kidney Early Evaluation Program (KEEP).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PURDUE PHARMA LLP via CAPITOL HILL CONSULTING GROUP
2009 · second_quarter · Q2
Controlled Drug Substances Act (21 USC 13)
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement
general healthcare issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety; Food and Drug Administration Amendments Act of 2007 (Public Law No. 110-85)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OKLAHOMA STATE UNIVERSITY CENTER FOR HEALTH SCIENCES via CAPITOL HILL CONSULTING GROUP
2009 · second_quarter · Q2
general appropriations for OSU-CHS; FY2010 Labor/HHS/Education Appropriations Bills
general healthcare issues pertaining to OSU-CHS, including but not limited to: Information Technology; access provider education; Veterans health care; American Recovery and Reinvestment Act (HR1)
general Medicare and Medicaid issues, including but not limited to, coverage and reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via CAPITOL HILL CONSULTING GROUP
2009 · second_quarter · Q2
general Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
general healthcare issues related to pharmaceutical and biological products; Federal, Food Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Follow-on Biologics; Comparative Effectiveness: Comparative Effectiveness Reserach Act (S.3408); Enhanced Health Care Value for All Act (HR2184); Promoting Innovation and Access to Life-saving Medicine Act (HR1427/S.726); Biologics Price Competition and Innovation Act of 2007 (S.1695); Pathway for Biosimilars Act (HR1548); Health Reform; Affordable Health Choices Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US via CAPITOL HILL CONSULTING GROUP
2009 · second_quarter · Q2
issues pertaining to antimicrobial resistance; community and healthcare associated infections and organ transplantation
issues related to: Medicare coverage of immunosuppressants; Medicare Part D's six classes of clinical concern, Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act HR1458/S.565
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDO PHARMACEUTICALS via CAPITOL HILL CONSULTING GROUP
2009 · second_quarter · Q2
general Medicare and Medicaid issues, including but not limited to, coverage and reimbursement.
general Medicare and Medicaid issues, including but not limited to, coverage and reimbursement. General healthcare issues, including but not limited to, drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (HR163); The Pharmaceutical Market Access and Drug Safety Act (S.525)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via CAPITOL HILL CONSULTING GROUP
2009 · first_quarter · Q1
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; Physician Gifts: Physician Payments Sunshine Act (S. 2029); Drug and Medical Device Company Gift Disclosure Act (H.R. 3023); False Claims Act Correction Act (H.R. 4854/S.2041); Medicare Part D: Non-interference; Medicare Prescription Drugs and Modernization Act (Public Law 108-173)
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug, and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Drug Safety: Food and Drug Administration Amendments Act of 2007 (Public Law No:110-85); FDA Globalization Act (H.R. 759); Comparative Effectiveness: Comparative Effectiveness Research Act (S. 3408); American Recovery and Reinvestment Act of 2008 (Public Law No. 111-5)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via CAPITOL HILL CONSULTING GROUP
2009 · first_quarter · Q1
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement.
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); FDA Globalization Act (H.R. 759); Follow-on Biologics; Comparative Effectiveness: Comparative Effectiveness Research Ace (S. 3408); Enhanced Health Care Value for All Act (H.R. 2184); Promoting Innovation and Access to Life-saving Medicine Act (H.R. 1427/S.726); Biologics Price Competition and Innovation Act (S.1695)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DFB PHARMACEUTICALS INC via CAPITOL HILL CONSULTING GROUP
2009 · first_quarter · 1T
General Pharmaceutical Issues pertaining to the company. No specific legislation
General healthcare issues related to pharmaceutical products. No specific legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OKLAHOMA STATE UNIVERSITY CENTER FOR HEALTH SCIENCES via CAPITOL HILL CONSULTING GROUP
2009 · first_quarter · Q1
General Healthcare issues pertaining to OSU-CHS, including but not limited to: Information Technology; Access; Provider Education; the Stimulus Bill
General Appropriations for OSU-CHS; FY09 Labor/HHS/Education Appropriations Bills
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement. Medicare Improvements for Patients and Providers Act (HR6331)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PURDUE PHARMA LLP via CAPITOL HILL CONSULTING GROUP
2009 · first_quarter · Q1
General healthcare issues related to pharmaceuticall and biological products; Federal Food, Drug and Cosmetic Act (21USC 9); Drug Safety; Food and Drug Administration Amendments Act of 2007 (Public Law No.l10-85); FDA Globalization Act (HR 759)
Controlled Drug Substances Act (21 USC 13)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDO PHARMACEUTICALS via CAPITOL HILL CONSULTING GROUP
2009 · first_quarter · Q1
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement. General health care issues, including but not limited to, drug importation
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement. General Healthcare issues, including but not limited to, drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (HR163); and The Pharmaceutical Market Access and Drug Safety Act (S.525)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS CORPORATION via CAPITOL HILL CONSULTING GROUP
2009 · first_quarter · Q1
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); drug safety; Food and Drug Administration Amendments Act of 2007 (Public Law No:110-85); FDA Globalization Act (HR 759); Follow-on biologics: American Recovery and Reinvestment Act of 2009 (Public Law No. 111-5)
FDA funding issues, generally, FY2009 Labor-HHS Appropriations; FY 2009 Department of Defense Appropriations; FY 2009 Supplemental Appropriations. Vaccines: Funding for the Transformational Medical Technologies Initiative (TMTI)
NATIONAL KIDNEY FOUNDATION via CAPITOL HILL CONSULTING GROUP
2009 · first_quarter · Q1
Assist the NKF in securing federal funding for programs aimed at screening, and preventing chronic kidney disease; Requesting funding for the KEEP Program
Assist the NKF in securing federal funding for programs aimed at screening, and preventing chronic kidney disease; Requesting funding for the KEEP Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US via CAPITOL HILL CONSULTING GROUP
2009 · first_quarter · Q1
Issues pertaining to antimicrobial resistance; Issues pertaining to community and healthcare associated infections; Issues pertaining to organ transplantation.
Issues related to: Medicare coverage of immunosuppressants, Medicare Part D's six classes of clinical concern, Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Ace of 2007
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL KIDNEY FOUNDATION via CAPITOL HILL CONSULTING GROUP
2009 · first_quarter · RA
Assisting the NKF with federal funding to help prevent screen and prevent chronic kidney disease, a major expense in the United States healthcare budget.
Assisting the NKF with federal funding to help prevent screen and prevent chronic kidney disease, a major expense in the United States healthcare budget.
NATIONAL KIDNEY FOUNDATION via CAPITOL HILL CONSULTING GROUP
2009 · first_quarter · RR
Assisting the NKF with federal funding to help prevent screen and prevent chronic kidney disease, a major expense in the United States healthcare budget.
Assisting the NKF with federal funding to help prevent screen and prevent chronic kidney disease, a major expense in the United States healthcare budget.
ASTELLAS PHARMA US via CAPITOL HILL CONSULTING GROUP
2008 · fourth_quarter · 4A
Issues related to: Medicare coverage of immunosuppressants, Medicare Part D's six classes of clinical concern, Medicaid payment for hospital-acquired conditions; The Medicare Improvements for Patients and Providers Act Technical Corrections Act; , Amending Title XVIII of the SSA to ensure access to critical medications under Medicare Part D; S. 1951 and H.R. 3700, the Fair Medicaid Drug Payment Act, S. 2320 and H.R. 3282 , the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007 Issues related to implementation of Section 5001(c) of the Deficit Reduction Act of 2005; S. 3560, QI Program Supplemental Funding Act of 2008 -- the QI bill included language to protect critical medications under Part D originally in H.R. 6331/S. 1887.
Issues related to: Antibiotic exclusivity and Infectious disease control; H.R. 6432, S. 2313 and H.R. 3697, the Strategies to Address Antimicrobial Resistance (STAAR Act); S. 3560, QI Program Supplemental Funding Act of 2008; S Res 454 and H Res 988, designating March 2008 as MRSA Awareness Month
ASTELLAS PHARMA US via CAPITOL HILL CONSULTING GROUP
2008 · third_quarter · 3A
Issues related to: Antibiotic exclusivity and Infectious disease control; H.R. 6432, Animal Drug User Fee Amendments Act of 2008; S. 2313 and H.R. 3697, the Strategies to Address Antimicrobial Resistance (STAAR Act); S. 3560, QI Program Supplemental Funding Act of 2008; S Res 454 and H Res 988, designating March 2008 as MRSA Awareness Month
Issues related to: Medicare coverage of immunosuppressants, Medicare Part D's six classes of clinical concern, Medicaid payment for hospital-acquired conditions; The Medicare Improvements for Patients and Providers Act Technical Corrections Act; S. 1887, Medicare Access to Critical Medications Act and HR 3061, Amending Title XVIII of the SSA to ensure access to critical medications under Medicare Part D; S. 1951 and H.R. 3700, the Fair Medicaid Drug Payment Act S. 2320 and H.R. 3282, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007 Issues related to implementation of Section 5001(c) of the Deficit Reduction Act of 2005
ASTELLAS PHARMA US via CAPITOL HILL CONSULTING GROUP
2008 · second_quarter · 2A
Pharmaceutical and life sciences, including but not limited to, federal organ transplant and anti-infectives policy
Pharmaceutical and life sciences, including but not limited to: coverage and reimbursement issues under the Medicare and Medicaid programs
Pharmaceutical and life sciences, including but not limited to: The Federal Food, Drug and Cosmetic Act; the Hatch-Waxman Act; and drug safety
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US via CAPITOL HILL CONSULTING GROUP
2008 · first_quarter · 1A
Pharmaceutical and life sciences, including but not limited to, federal organ transplant and anti-infectives policy
Pharmaceutical and life sciences, including but not limited to: The Federal Food, Drug and Cosmetic Act; the Hatchwaxman Act; drug imporation; and drug safety
Pharmaceutical and life sciences, including but not limited to: Coverage and reimbursement issues under the Medicare and Medicaid programs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MCBRIDE CLINIC via CAPITOL HILL CONSULTING GROUP
2008 · third_quarter · 3T
General healthcare issues related to physician-owned specialty hospitals. Restrictions on physician-owned specialty hospitals included in the following bills: Mental Health Parity Act (S.558); Children's Health Insurance Program Reauthorization Act (HR 976); Medicare Improvements for Patients and Providers Act (HR 6331); Supplemental Appropriations Act (HR 2642).
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US via CAPITOL HILL CONSULTING GROUP
2008 · fourth_quarter · 4A
Issues related to: Antibiotic exclusivity and Infectious disease control; H.R. 6432, S. 2313 and H.R. 3697, the Strategies to Address Antimicrobial Resistance (STAAR Act); S. 3560, QI Program Supplemental Funding Act of 2008; S Res 454 and H Res 988, designating March 2008 as MRSA Awareness Month
Issues related to: Medicare coverage of immunosuppressants, Medicare Part D's six classes of clinical concern, Medicaid payment for hospital-acquired conditions; The Medicare Improvements for Patients and Providers Act Technical Corrections Act; , Amending Title XVIII of the SSA to ensure access to critical medications under Medicare Part D; S. 1951 and H.R. 3700, the Fair Medicaid Drug Payment Act, S. 2320 and H.R. 3282 , the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007 Issues related to implementation of Section 5001(c) of the Deficit Reduction Act of 2005; S. 3560, QI Program Supplemental Funding Act of 2008 -- the QI bill included language to protect critical medications under Part D originally in H.R. 6331/S. 1887.
PHRMA via CAPITOL HILL CONSULTING GROUP
2008 · fourth_quarter · Q4
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Drug safety: Food and Drug Administration Amendments Act of 2007 (Public Law No: 110-85); Food and Drug Import Safety Act (HR 3610); Drug reimportation: Pharmaceutical Market Access Act (S. 251); Pharmaceutical Market Access and Drug Safety Act (S. 242/HR 380). Comparative Effectiveness: Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (HR 2184).
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; Physician gifts: Physician Payments Sunshine Act (S. 2029); Drug and Medical Device Company Gift Disclosure Act (HR 3023); False Claims Act Correction Act (HR 4854/S. 2041); Medicare Part D: Non-interference; Medicare Prescription Drugs and Modernization Act (Public Law 108-173); Medicare Prescription Price Negotiation Act (HR 4/S. 3). Medicare Improvements for Patients and Providers Act (HR 6331)
DFB PHARMACEUTICALS INC via CAPITOL HILL CONSULTING GROUP
2008 · fourth_quarter · Q4
General Pharmaceutical Issues pertaining to the company. No specific legislation.
General healthcare issues related to pharmaceutical products. Federal, Food, Drug and Cosmetic Act (21 USC 9)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS CORPORATION via CAPITOL HILL CONSULTING GROUP
2008 · fourth_quarter · Q4
FDA funding issues, generally. FY2009 Labor-HHS Appropriations; FY2009 Department of Defense Appropriations; FY2009 Supplemental Appropriations. Vaccines: Funding for the Transformational Medical Technologies Initiative (TMTI)
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Drug safety: Food and Drug Administration Amendments Act of 2007 (Public Law No: 110-85); Food and Drug Import Safety Act (HR 3610); Drug reimportation: Pharmaceutical Market Access Act (S. 251); Pharmaceutical Market Access and Drug Safety Act (S. 242/HR 380). Follow-on biologics: Access to Life-Saving Medicine Act (HR 1038); Patient Protection and Innovative Biologic Medicines Act (HR 1956); Biologics Price Competition and Innovation Act (S. 1695); Pathway for Biosimilars Act (HR 5629). Comparative Effectiveness: Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (HR 2184).
OKLAHOMA STATE UNIVERSITY CENTER FOR HEALTH SCIENCES via CAPITOL HILL CONSULTING GROUP
2008 · fourth_quarter · Q4
general appropriation for OSU-CHS; FY09 Labor/HHS/Education Appropriations Bills
general Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement. Medicare Improvements for Patients and Providers Act (HR 6331)
General Healthcare issues pertaining to OSU-CHS, including but not limited to: Information Technology; access; and provider education
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US via CAPITOL HILL CONSULTING GROUP
2008 · fourth_quarter · Q4
Issues related to: Medicare coverage of immunosuppressants, Medicare Part D's six classes of clinical concern, Medicaid payment for hospital-acquired conditions; The Medicare Improvements for Patients and Providers Act Technical Corrections Act; S. 1887, Medicare Access to Critical Medications Act and HR 3061, Amending Title XVIII of the SSA to ensure access to critical medications under Medicare Part D; S. 1951 and H.R. 3700, the Fair Medicaid Drug Payment Act; S. 2320 and H.R. 3282, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007 Issues related to implementation of Section 5001(c) of the Deficit Reduction Act of 2005
Issues related to: Antibiotic exclusivity and Infectious disease control; H.R. 6432, S. 2313 and H.R. 3697, the Strategies to Address Antimicrobial Resistance (STAAR Act); S. 3560, QI Program Supplemental Funding Act of 2008; S Res 454 and H Res 988, designating March 2008 as MRSA Awareness Month
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via CAPITOL HILL CONSULTING GROUP
2008 · fourth_quarter · Q4
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement. Physician gifts: Physician Payments Sunshine Act (S. 2029); Drug and Medical Device Company Gift Disclosure Act (HR 3023); False Claims Act Correction Act (HR 4854/S. 2041); Medicare Part D: Non-interference; Medicare Prescription Drugs and Modernization Act (Public Law 108-173); Medicare Prescription Price Negotiation Act (HR 4/S. 3). Medicare Improvements for Patients and Providers Act (HR 6331); Supplemental Appropriations Act (HR 2642).
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9) Public Health Service Act (42 USC 6A); Drug safety: Food and Drug Administration Amendments Act of 2007 (Public Law No: 110-85); Food and Drug Import Safety Act (HR 3610); Drug reimportation: Pharmaceutical Market Access Act (S. 251); Pharmaceutical Market Access and Drug Safety Act (S. 242/HR 380). Follow-on biologics: Access to Life-Saving Medicine Act (HR 1038); Patient Protection and Innovative Biologic Medicines Act (HR 1956); Biologics Price Competition and Innovation Act (S. 1695); Pathway for Biosimilars Act (HR 5629). Comparative Effectiveness: Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (HR 2184).
PURDUE PHARMA LLP via CAPITOL HILL CONSULTING GROUP
2008 · fourth_quarter · Q4
Controlled Drug Substances Act (21 USC 13)
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Drug safety: Food and Drug Administration Amendments Act of 2007 (Public Law No: 110-85); Food and Drug Import Safety Act (HR 3610); Drug reimportation: Pharmaceutical Market Access Act (S. 251); Pharmaceutical Market Access and Drug Safety Act (S. 242/HR 380
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDO PHARMACEUTICALS via CAPITOL HILL CONSULTING GROUP
2008 · fourth_quarter · Q4
general Medicare and Medicaid issues, including but not limited to, coverage and reimbursement. General health care issues, including but not limited to, drug importation
general Medicare and Medicaid issues, including but not limited to, coverage and reimbursement. General health care issues, including but not limited to, drug importation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General FDA funding issues; FY2012 Labor-HHS-Education Appropriations; Pandemic vaccine issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FDA funding issues, generally; FY 2010 Labor-HHS-Labor Appropriations; FY2010 Supplemental Appropriations; Pandemic vaccine issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; Physician Payments Sunshine Act (S.301)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug, and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); follow-on biologics; America's Affordable Health Choices Act (H.R. 3200); Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Act (H.R. 3590)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General Patent Issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General Meidcare and Medicaid issues, including but not limited to, coverage and reimbursement; Physician gifts; Physician Payments Sunshine Act (S.301)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FDA funding issues, generally, FY2010 Labor-HHS Appropriations; FY2010 Supplemental Appropriations; Pandemic vaccine issues; American Recovery and Reinvestment Act (HR1)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
general patent issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; Physician gifts; Physician Payments Sunshine Ace (S. 2029); Drug and Medical Device Company Gift Disclosure Act (HR 3023); False Claims Act Correction Act (HR 4854/S. 2041)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; Physician gifts: Physician Payments Sunshine Act (S. 2029); Drug and Medical Device Company Gift Disclosure Act (HR 3023); False Claims Act Correction Act (HR 4854/S. 2041); Medicare Part D: Non-interference; Medicare Prescription Drugs and Modernization Act (Public Law 108-173); Medicare Prescription Price Negotiation Act (HR 4/S. 3). Medicare Improvements for Patients and Providers Act (HR 6331); Supplemental Appropriations Act (HR 2642).
general patent issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE